Future Considerations for Pneumococcal Vaccination
August 30th 2024The key opinion leaders examine the recent approval of PCV21, assessing its potential influence on pneumococcal vaccination strategies, while also identifying and discussing current unmet needs in the field of pneumococcal vaccination.
Insights on Conjugate Pneumococcal Vaccines
August 30th 2024The vaccination experts analyze the impact of currently approved pneumococcal vaccines on otitis media prevention and compare the newer conjugate vaccines (PCV15 and PCV20) to their predecessors in terms of strain coverage and clinical efficacy.
Clinical Data Supporting Pneumococcal Vaccination
August 23rd 2024Key opinion leaders examine the pivotal clinical data that supported the FDA approvals of PCV15, PCV20, and PCV21, while also explaining the differences between polysaccharide and conjugate pneumococcal vaccines in terms of their induced immune responses and the durability of protection they offer.
Clinical Considerations for Pneumococcal Vaccination Scheduling
August 23rd 2024The medical experts explore the importance of receiving PCV20 following PCV13 and PPSV23 vaccinations, while also delving into the broader discussion of how sequential administration of these pneumococcal vaccines may potentially enhance protection against targeted strains.